Presently, PD-L1 assessment relies on immunohistochemistry (IHC) conducted on postoperative samples, which may not provide a comprehensive representation of the entire tumour, leading to potential inaccuracies. Immuno-positron emission tomography (immuno-PET) represents an innovative imaging technique offering real-time, quantitative insights into PD-L1 expression levels. By employing radiolabelled molecules designed to target PD-L1, researchers can non-invasively monitor PD-L1 levels within tumours with improved precision.
Early experiments involving immuno-PET imaging in glioblastoma have yielded encouraging results. Radiolabelled agents designed to target PD-L1 exhibited rapid accumulation within tumours, facilitating clear imaging outcomes within a remarkably short time frame. While challenges persist, immuno-PET holds significant promise for advancing our understanding of how glioblastoma respond to immunotherapy and prioritise treatment for patients to improve outcome.
Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma - Cancers (Basel). 2023 Jun 9;15(12):3131.
Gitanjali Sharma, Marta C Braga, Chiara Da Pieve, Wojciech Szopa, Tatjana Starzetz, Karl H Plate, Wojciech Kaspera, Gabriela Kramer-Marek